HIV inhibitors: Problems and reality

Annals of the New York Academy of Sciences

Volumn 946, Issue , 2001, Pages 145-159

  Tozser J ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

HIV 1; Inhibitors; Replication enzymes; Resistance; Side effects

Indexed keywords

ABACAVIR; ADEFOVIR DIPIVOXIL; AMPRENAVIR; ANTIRETROVIRUS AGENT; CYTOCHROME P450 3A; DELAVIRDINE; DIDANOSINE; DNA DIRECTED DNA POLYMERASE; DNA DIRECTED DNA POLYMERASE GAMMA; EFAVIRENZ; INDINAVIR; INTEGRASE; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEINASE; PROTEINASE INHIBITOR; RETINOIC ACID BINDING PROTEIN; RETINOID X RECEPTOR; RIBONUCLEASE H; RITONAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

CARDIOVASCULAR DISEASE; CONFERENCE PAPER; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; LIPODYSTROPHY; VIRUS LOAD; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES; STAPHYLOCOCCUS PHAGE 3A;

EID: 0035198010     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2001.tb03909.x     Document Type: Conference Paper

References (38)

1. The retroviral enzymes
2. Retroviral virions and genomes
3. Retroviral proteinases
4. Specificity of retroviral proteinases based on substrates containing tyrosine and proline at the site of cleavage
5. Substitution of proline with pipecolic acid at the scissile bond converts a peptide substrate of HIV proteinase into a selective inhibitor
6. Inhibitors of HIV-1 protease: A major success of structure-assisted drug design
7. Limits to potent antiretroviral therapy
8. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy
9. Interactions between drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase
10. Incidence and impact of resistance against approved antiretroviral drugs
11. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection
12. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors
13. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites
14. Severe adverse cutaneous reactions to drugs
15. Adverse effects of antiretroviral therapy
16. Mitochondrial toxicity of antiviral drugs
17. Effects of protease inhibitors on hyperglycemia, hyperlipidemia and lipodystrophy
18. Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: Mechanism-based inactivation of cytochrome P450A3 by ritonavir
19. Role of P-glycoprotein and cytochrome P450 3A in limiting oral adsorption of peptides and peptidomimetics
20. Pathogenesis of HIV protease inhibitor-associated syndrome of peripheral lopodystrophy, hyperlipidaemia and insulin resistance
21. Inhibition of adipocyte differentiation by HIV protease inhibitors
22. HIV-1 protease inhibitors decrease proliferation and induce differentiation of human myelocytic leukemia cells
23. The mechanism of insulin resistance caused by HIV proteinase inhibitor therapy
24. A syndrome of lipoathrophy, lactic acidemia and liver dysfunction associated with HIV nucleoside analogue therapy: Contribution to protease inhibitor-related lipodystrophy syndrome
25. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy
26. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy
27. Protease inhibitor-associated hyperglycaemia
28. Severe diabetes associated with protease inhibitor therapy
29. New-onset diabetes mellitus associated with use of protease inhibitors
30. Signaling mechanisms that regulate glucose transport
31. Molecular basis of insulin-stimulated GLUT4 vesicle trafficking. Location! Location! Location!
32. Identification of a novel gene encoding an insulin-responsive glucose transporter protein
33. Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes
34. Cardiac and adipose tissue abnormalities but not diabetes in mice deficient in GLUT4
35. Vascular complications associated with use of HIV protease inhibitors
36. Severe premature coronary artery disease with protease inhibitors
37. Myocardial infarction in HIV-infected men receiving protease inhibitors
38. Extensive polymorphism observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays